Go to deals
Healthcare

Protalix BioTherapeutics, Inc. has completed a private stock placement

Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.

Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Ruben  Eblagon

Ruben Eblagon

Principal

Tel Aviv, Israel
Oaklins Rosario
 Boaz  Levi

Boaz Levi

Partner

Tel Aviv, Israel
Oaklins Rosario
 Olga  Geyber

Olga Geyber

Support

Tel Aviv, Israel
Oaklins Rosario

Related deals

S.I.CON S.r.l. has acquired Acqua Vera from Sanpellegrino S.p.a.
Food & Beverage

S.I.CON S.r.l. has acquired Acqua Vera from Sanpellegrino S.p.a.

S.I.CON S.r.l. has acquired Acqua Vera from Nestlé-owned Sanpellegrino S.p.a.

Learn more
S.R. Accord has issued bonds worth US$55 million
Financial Services

S.R. Accord has issued bonds worth US$55 million

S.R. Accord Ltd. has completed a fundraising to refinance and develop the company.

Learn more
Navitas Petroleum has issued bonds worth US$117 million
Energy

Navitas Petroleum has issued bonds worth US$117 million

Navitas Petroleum has completed a fundraising to refinance and develop the company.

Learn more